Intriguingly, a comparative analysis performed in A375 melanoma cells showed higher antiproliferative activity of amodiaquine when compared to chloroquine, which was confirmed by array analysis, revealing the modulation of gene expression antagonizing cell cycle progression (upregulation of CDKN1A and downregulation of E2F1) and modulation of the genes TP53, CDKN1A, E2F1, CCND1, and phosphorylated RB1. Here, TP53 is linked to melanoma.